QX008N
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human
|
IL7R |
QX008N binds human TSLP with a high affinity (Kd = 0.0175 nM) that is superior to the Tezepelumab (HY-P99366A) analog[1].
QX008N (2 μg/mL initial concentration, 1:5 gradient dilutions) specifically binds human, cynomolgus monkey, and rhesus macaque TSLP[1].
QX008N potently inhibits the interaction between human TSLP and the TSLPR-IL-7Rα complex[1].
QX008N (2 μg/mL initial concentration, 1:3 gradient dilutions) potently neutralizes TSLP-induced JAK/STAT signaling in SW756-STAT5-Luciferase cells exposed to recombinant human, natural human, or recombinant cynomolgus monkey TSLP[1].
QX008N (10 concentration points via 1:5 gradient dilutions) potently inhibits human TSLP-induced CCL17 secretion in human PBMCs (IC50 = 9.836 ng/mL) and whole blood (IC50 = 1.599 ng/mL), and CCL22 secretion in human PBMCs, with activity superior to the Tezepelumab analog[1].
QX008N, when combined with anti-IL-4R antibody Oturkibart (HY-P991152), potently inhibits CCL17 production in human PBMCs stimulated with TSLP, IL-4, IL-13, and IL-33, achieving 95.5% inhibition that exceeds the additive effect of monotherapies[1].
QX008N (6 day incubation), when combined with anti-IL-4R antibody QX005N, enhances inhibition of OVA-induced CCL17, IL-5, and CCL26 production in a ternary culture model of MRC-5 fibroblasts, A549 epithelial cells, and human PBMCs, compared to QX008N monotherapy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey (male, 3-6 years, 2.5-7.0 kg, sensitized via intraperitoneal injection of Ascaris suis extract mixed with Al(OH)3 adjuvant at weeks 1, 2, and 3, followed by nebulized allergen challenge at weeks 4-7)[1]
-
Dosage:10 mg/kg; 50 mg/kg
-
Administration:once weekly; 6 doses; subcutaneous injection
-
Result:Decreased percentage change in airway resistance by 25% and increased percentage change in lung dynamic compliance by 20% at one week after three 10 mg/kg doses.
Reduced peripheral blood specific IgE by ~38% after three 10 mg/kg doses and TSLP by ~42% after six 10 mg/kg doses.
Decreased percentage change in airway resistance by 42.4% and increased percentage change in lung dynamic compliance by 30% at one week after first 50 mg/kg dose.
Reduced peripheral blood TSLP by ~66% and specific IgE by ~62% after first 50 mg/kg dose.
Lowered TSLP levels, eosinophil counts and eosinophil percentage in bronchoalveolar lavage fluid at 10 mg/kg and 50 mg/kg.
Attenuated eosinophil infiltration in lung tissue at 10 mg/kg and 50 mg/kg.
Reached plasma concentration of 336.3 μg/mL after first 50 mg/kg dose.
Q969D9-1
TSLP
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
QX008N 関連分類
HY-P992447 関連分類
Powered by Bioz